President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers than others, according to some analysts.
Trump told reporters earlier this month that his administration will begin implementing low pharmaceutical levies as early as Aug. 1 and increase the rate in about a year or 18 months. He has threatened to impose up to 200% tariffs on imported drugs.
It is still unclear if he will follow through with that exact plan and tariff rate, which makes it difficult to fully assess how the policy will affect drugmakers and patients. Domestic drug manufacturing operations are also growing, as several companies have recently announced multi-billion-dollar investments in new facilities to build goodwill with the president, but it will likely take several years before those sites are up and running.
Some analysts have estimated the potential tariff risk to different companies based on their current manufacturing networks, among other factors.
AbbVie
